In-house roundup: Poll shows UPC attractive without UK; generics support European SPC system; antibody case law better in US than Europe

Survey: UPC still attractive without UK 

In a Patent Strategy poll of more than 50 in-house counsel, 78% of respondents said a harmonised European patent system would still be useful if a post-Brexit UK were unable to participate. Read more... 

Poll: SPC system wanted by most generics 

In part two of Patent Strategy’s survey, almost all in-house respondents backed a European SPC system, but were less unified on the SPC Regulation’s reliability for new technologies or third-party MAs. Read more... 

Antibody case law clearer in the US than Europe 

Pharma innovators say clearer standards on how monoclonal antibody patent applications are reviewed at the USPTO and US national courts have made it easier to file patents there than at the EPO. Read more... 

Share this article